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Abbreviations used in the text 1 
                                                           
1 BTX-A (botulinum toxin A), SNAP-25 (synaptosomal-associated protein 25), s.c. (subcutaneous), i.m. 
(intramuscular), i.n. (intraneural), PBS (phosphate-buffered saline), NGS (normal goat serum), SDS (sodium 
dodecyl sulphate), BTX-E (botulinum toxin E) 
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Abstract: 
Axonal transport of enzymatically active botulinum toxin A (BTX-A) from periphery to the CNS 
has been described in facial and trigeminal nerve, leading to cleavage of synaptosomal-
associated protein 25 (SNAP-25) in central nuclei. Aim of present study was to examine the 
existence of axonal transport of peripherally applied BTX-A to spinal cord via sciatic nerve.  
We employed BTX-A-cleaved SNAP-25 immunohistochemistry of lumbar spinal cord after 
intramuscular and subcutaneous hind limb injections, and intraneural BTX-A sciatic nerve 
injections. Truncated SNAP-25 in ipsilateral spinal cord ventral horns and dorsal horns appeared 
after single peripheral BTX-A administrations, even at low intramuscular dose applied (5 U/kg). 
Cleaved SNAP-25 appearance in the spinal cord after BTX-A injection into the sciatic nerve was 
prevented by proximal intrasciatic injection of colchicine (5 mM, 2 µl). Cleaved SNAP-25 in 
ventral horn, using choline-acetyltransferase (ChAT) double labeling, was localized within 
cholinergic neurons. 
These results extend the recent findings on BTX-A retrograde axonal transport in facial and 
trigeminal nerve. Appearance of truncated SNAP-25 in spinal cord following low-dose 
peripheral BTX-A suggest that the axonal transport of BTX-A occurs commonly following 
peripheral application.  
Highlights: > Peripheral BTX-A cleaves SNAP-25 in dorsal and ventral horn of the spinal cord. 
> Axonal transport of BTX-A occurs at low intramuscular dose.> BTX-A retrograde transport 
occurs via peripheral nerves and is microtubule-dependent. > In ventral horn truncated SNAP-25 
was localized within cholinergic neurons 
Keywords: botulinum toxin A, synaptosomal-associated protein 25, retrograde axonal transport, 
spinal cord, peripheral nerve, immunohistochemistry 
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1. INTRODUCTION 
It is a textbook knowledge that botulinum toxin type A (BTX-A) in botulism, as well as in 
therapeutic applications, exerts the neuromuscular paralysis by enzymatic cleavage of peripheral 
synaptosomal-associated protein 25 (SNAP-25), involved in neuroexocytosis. Unlike related 
tetanus toxin, which is known to be retrogradely transported and transcytosed to second-order 
synapses (Schwab et al., 1979), it was generally accepted that BTX-A acts directly only on 
peripheral nerve endings. Nevertheless, already in the 70-ties some authors reported axonal 
transport of radioactively labeled botulinum toxin A (BTX-A) within peripheral nerves to spinal 
cord (Habermann, 1974; Wiegand et al., 1976). Those observations remained forgotten and 
questioned in later studies (Tang Liu et al., 2003). Main objections to these early studies were 
that it was not known if radioactively labeled BTX-A retained the enzymatic activity by the time 
it reached spinal cord. However, axonal transport of functional BTX-A molecules was recently 
found in hippocampus, visual system and in facial motoneurons (Antonucci et al., 2008). BTX-A 
axonal transport followed by enzymatic cleavage in CNS has been demonstrated in trigeminal 
sensory neurons (Matak et al., 2011). Recent in vitro study suggests spread of BTX-A within cell 
bodies and distal processes of cultured sympathetic neurons (Lawrence et al., 2011). 
Retrograde axonal transport of low dose BTX-A in spinal sensory neurons has been suggested by 
behavioral experiments in models of bilateral muscular hyperalgesia (Bach-Rojecky & Lacković, 
2009) and diabetic neuropathy (Bach-Rojecky et al., 2010). 
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In present study we found the enzymatic activity of BTX-A in rat motor and sensory regions of 
the spinal cord after intramuscular, subcutaneous, or intraneural toxin application. 
  
2. MATERIALS & METHODS  
2.1 Animals 
18  male Wistar rats (University of Zagreb School of Medicine, Croatia), weighing 300-400 g, 
kept on 12 h/12h light and dark cycle with unlimited access to food and water, 3 months old, 
were used. Experiments were conducted according to the European Communities Council 
Directive (86/609/EEC). Animal procedures were approved by the Ethical Committee of 
University of Zagreb, School of Medicine (permit No. 07-76/2005-43). All efforts were made to 
reduce the suffering of animals and the number of animals used.  
 
2.2 Experimental procedure 
Animals were injected unilaterally with BTX-A (Botox, Allergan, Irvine, CA , USA) diluted in 
0.9%  saline. One international unit (1 U) of BTX-A, equal to mouse LD50, contains 
approximately 48 pg of 900 kDa neurotoxin. Animals were divided into 6 treatment groups (3 
animals per group): group 1: BTX-A injected subcutaneously (s.c.) into the plantar side of hind-
paw pad (30 U/kg, in volume of 30 µl); groups 2 and 3: BTX-A injected intramuscularly (i.m.) 
into the gastrocnemius (5 U/kg and 30 U/kg, 30 µl). In groups 4 and 5 BTX-A was injected 
intraneurally (i.n.) into the sciatic nerve (10 U/kg, 2 µl). 2 µl of 5 mM axonal transport blocker 
colchicine (Sigma, St. Louis, MO, USA) (group 4) or saline (group 5) were injected into the 
sciatic nerve 24 h prior to the more distal i.n. injections of BTX-A. To reduce the number of 
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animals in the experiment, single control group (group 6) consisting of 0.9% saline (i.m.) - 
treated animals was used.  
5 U/kg low dose and 30 U/kg BTX-A high dose was chosen based on previous experiments (Cui 
et al, 2004; Bach-Rojecky et al., 2005), and 10 U/kg dose was chosen based on preliminary data. 
5 U/kg dose in humans (350 U for a 70 kg average human) is within the dose-range regularly 
used for treatment of spasticity (Intiso, 2012).  
For i.m. and s.c. injections rats were restrained, while for the i.n. injections animals were deeply 
anesthetized (chloral hydrate, Sigma, St. Louis, MO, USA; 300 mg/kg intraperitoneally). Sciatic 
nerve was exposed after skin incision at mid-femoral level and blunt dissection through the thigh 
muscles. Special care was made to check for possible leakage by placing piece of parafilm under 
the nerve prior to i.n. injection. 0-10 µl Hamilton needle (Hamilton, Bonaduz, Switzerland) was 
used to inject saline/colchicine and BTX-A into the nerves. 3 minutes following the treatment, 
parafilm was removed, the nerve returned to previous position and the skin sutured. After the 
operation animals were left to recover from anesthesia under warm bulb light and returned to 
their cages.  
 
2.3 Immunohistochemistry 
Animal preparation and immunohistochemistry was performed similarly as previously described 
(Matak et al., 2011, Antonucci et al., 2008). In brief, 5 days after BTX-A s.c and i.m. injections 
or 3 days following i.n. injections, rats were deeply anesthetized with chloral hydrate and 
transcardially perfused with 0.9 % saline followed by fixative (4% paraformaldehyde in 0.01 M 
phosphate-buffered saline (PBS)). Lumbal spinal cords were removed, cryoprotected in sucrose 
(15% in fixative for 1 day and 30% in PBS for 2 days), and kept on -80 ºC until further use. 40 
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µm spinal cord coronal sections were cut on a freezing microtome and transferred to PBS-filled 
wells for free floating. Following blocking in PBS-diluted 10% normal goat serum (NGS), the 
sections were incubated with 1: 600 anti-BTX-A-cleaved SNAP-25 rabbit polyclonal antibody (a 
kind gift from prof. Ornella Rossetto, University of Padua, Italy) diluted in PBS with 1% NGS, 
overnight at room temperature, and the following day with fluorescently-labeled secondary 
antibody in dark (goat anti-rabbit Alexa-Fluor 555, Invitrogen, Carlsbad, CA, USA). Sections 
were then blocked again and counterstained with mouse monoclonal antibody for neurons (Anti-
NeuN, Millipore, Temecula, CA, USA) (1:500 dilution overnight at 4ºC), and the next day with 
secondary anti-mouse Alexa-Fluor 488 (Invitrogen, Carlsbad, CA, USA). 
Sections were washed with PBS, mounted on glass slides with antifading agent (Fluorogel, 
Electron Microscopy Sciences, Hatfield, PA,USA), and visualized with fluorescence microscope 
equipped with appropriate filters (Olympus BX51, Olympus, Tokyo, Japan) and digital camera 
(Olympus DP-70). Double-label images were composed with Olympus DP Manager software, 
assembled with Microsoft Paint and then processed for brightness and contrast using Adobe 
Photoshop. We checked for the appearance of cleaved SNAP-25 immunoreactivity in 20-25 
lumbal spinal cord sections from each animal. In the figures, to show the data of one 
experimental qroup, representative image from single animal was chosen.  
2.4 Colocalization study 
. L5 spinal cord sections from animals injected with 30U/kg s.c. were blocked with donkey 
serum and incubated overnight at room temperature with primary antibodies for cleaved SNAP-
25, and for choline acetyltransferase (Millipore, Temecula, CA, USA), produced in goat, 1:100 
dilution. The next day sections were incubated with secondaries: donkey anti-rabbit Alexa Fluor 
488 and donkey anti-goat 546. In second experiment sections were blocked with goat serum and 
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incubated with anti-cleaved SNAP-25 and mouse anti-glial fibrilary acidic protein (Sigma, St. 
Louis, MO, USA, 1:1000) overnight at room temperature. The next day sections were incubated 
with secondary goat anti-mouse Alexa Fluor 546 and goat anti-rabbit Alexa Fluor 488 
(Invitrogen, Carlsbad, CA, USA). Spinal cord ventral horns were visualized with confocal laser 
scanning microscope (Leica TCS SP2 AOBS), using 488 and 543 nm lasers.  
     
3. RESULTS 
Slight ipsilateral flaccidity of rat distal hind limb was visible only following the i.m. treatment (5 
and 30 U/kg of BTX-A), but not following the i.n. or s.c. injections. 
BTX-A-cleaved SNAP-25 immunoreactivity appeared in ipsilateral lumbal ventral horns of s.c., 
i.m. and i.n.- BTX-A treated animals (Figures 1 and 2). Cleaved SNAP-25 immunoreactivity was 
visible around motoneuronal nuclei of lamina 9 in the form of dense, small fibers, and long 
neuronal processes, which also extended into the lamina 7 (Figures 1 and 2).  Following i.m. and 
i.n. injections, truncated SNAP-25 occurred in L4, mainly in laminas 7 and 9, while following 
s.c. injection, strongest immunolabeling occurred in L5 segment ventral horn lamina 9 (Figure 
1). Following intrasciatic saline + BTX-A injection at mid-thigh level, truncated SNAP-25 
immunoreactivity was more widespread rostro-caudally (L3-L5).  
Intramuscularly applied low-dose BTX-A (5 U/kg) also resulted in ventral horn SNAP-25 
cleavage (Figure 2B). Intensity of cleaved SNAP-25 in ventral horn following 5 U/kg i.m. 
injection, although not quantified, was apparently lower than after higher doses (30 U/kg i.m. 
and s.c).  
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BTX-A enzymatic activity in the form of individual fibers appeared in ipsilateral dorsal horn 
even at small peripheral i.m. (5 U/kg) dose (Figure 2A), and following higher dose i.m., i.n. and 
s.c. injections (not shown), thus, indicating the axonal transport in spinal sensory neurons.   
Intrasciatic colchicine pretreatment abolished the cleaved SNAP-25 immunoreactivity in spinal 
cord of BTX-A (i.n.) treated animals, thus, demonstrating the microtubule-dependent retrograde 
axonal transport of BTX-A through sciatic nerve (Figures 2C and D).  
To examine the cellular localization of cleaved SNAP-25 in spinal cord motor region, we 
performed colocalization study with markers of cholinergic neurons and astrocytes. Cleaved 
SNAP-25 was found to colocalize with choline acetyl transferase (ChAT) - positive fibers, most 
likely belonging to proximal dendrites of motor neurons (Figure 3A). Cleaved SNAP-25 did not 
colocalize with glilal fibrillary acidic protein (GFAP), marker of astrocytes (Figure 3B).    
Figure 1 
Figure 2 
Figure 3 
 
4. DISCUSSION 
 
4.1 Occurrence of cleaved SNAP -25 in the spinal cord after BTX-A peripheral injections  
Cleavage of central SNAP-25 in ipsilateral spinal cord segments after single peripheral 
application of BTX-A suggests the long-distance axonal traffic of enzymatically active BTX-A 
fragments from periphery to the spinal cord. These results extend recent findings on retrograde 
axonal transport of functionally active BTX-A in cranial nerves (Antonucci et al., 2008, Matak et 
al., 2011). Importantly, apart from cranial nerves in facial region with relatively short axons 
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which project to the rat brainstem, this study shows BTX-A axonal transport to CNS over longer 
distances. Present immunohistochemical evidence of axonal transport to spinal cord is in line 
with previous behavioral findings, where inhibition of axonal transport in the rat sciatic nerve 
abolished BTX-A antinociceptive effects in a model of bilateral pain (Bach-Rojecky and 
Lacković, 2009).  
To examine the traffic within peripheral nerves we applied BTX-A directly into the sciatic nerve. 
Occurrence of truncated SNAP-25 in spinal cord after i.n. injection, preventable by proximally 
applied colchicine, shows that BTX-A is retrogradely transported through the peripheral nerve 
by means of microtubule-dependent axonal transport. 
The effect of intrasciatic injection of BTX-A on pain behavior was reported before (Bach-
Rojecky and Lacković, 2009). How the BTX-A enters the sciatic axons is unknown.  BTX-A 
uptake into the peripheral nerve endings is mediated by SV2C-receptor mediated endocytosis 
(Mahrhold et al., 2006). If the similar mechanism exists in axons is not known. Another 
possibility is that BTX-A diffuses into the axoplasm through damaged axons, caused by i.n. 
injection itself. 
In this study we found that cleaved SNAP-25 was localized in ChAT- positive cholinergic fibers 
surrounding the motoneuronal cell bodies. This finding indicates that, after axonal transport from 
periphery, botulinum toxin cleaves SNAP-25 most likely in primary motor neurons. However, 
the possibility that botulinum toxin, following transcytosis, enters cholinergic nerve terminals of 
neurons other than motoneurons cannot be ruled out completely. Novel study described the 
cleavage of SNAP-25 in the muscles of contralateral forelimb following peripheral BTX-A 
forelimb injection, thus, indicating the possibility of transcytosis within the motor neurons (Torii 
et al., 2011). 
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In this study an indirect method of BTX-A detection (by cleaved SNAP-25 immunolabeling) was 
used. Antibody specificity to BTX-A-truncated and not to the intact SNAP-25 was previously 
confirmed by BTX-A injections into the rat hippocampus and SDS polyacrylamide gel 
electrophoresis followed by Western blot (Matak et al., 2011). Single 24 kDa band 
corresponding to truncated SNAP-25 was visible only in BTX-A-treated animals, and position of 
that band was confirmed using antibody which recognizes both cleaved and intact SNAP-25. 
This experiment excluded possible immunostaining due to the non-specific binding to intact 
SNAP-25, or due to endogenously cleaved SNAP-25 (Figure 1 from Matak et al., 2011).  
It can be argued that, instead of BTX-A, truncated SNAP-25 was transported from periphery to 
the spinal cord. Axonal transport of BTX-A was demonstrated previously in the visual system. 
Antonucci et al. (2008) injected BTX-A into the superior colliculus, and examined the 
occurrence of truncated SNAP-25 in the rat retina. Then, they cut the optic nerve and depleted 
the retina from truncated SNAP-25 by transiently active botulinum toxin E (BTX-E), which 
cleaves both intact and BTX-A-cleaved SNAP-25. After completion of BTX-E effects, BTX-A-
cleaved SNAP-25 re-appeared in the retina, demonstrating the presence of BTX-A protease. 
Low dose BTX-A (0.5 U/kg) injection into the distally cut rat sciatic nerve reduced contralateral 
pain in a bilateral pain model (Bach-Rojecky and Lacković, 2009), which, obviously, cannot be 
associated with peripheral SNAP-25 cleavage.  
In sensory system, occurrence of truncated SNAP-25 in CNS seems to be associated with toxin’s 
antinociceptive activity (Matak et al., 2011). On the other hand, significance of SNAP-25 
cleavage in central motor regions remains to be investigated.  
 
5. Conclusion 
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Appearance of truncated SNAP-25 in spinal cord following low dose i.m. BTX-A (5 U/kg) 
administration suggests that the axonal transport of toxin to CNS commonly occurs following 
peripheral administration.  
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Figure 1. Immunofluorescently labeled truncated SNAP-25 (red) in ipsilateral ventral horn of rat 
spinal cord (L5 segment) 5 days after subcutaneous BTX-A (30 U/kg) injection into the hind-
paw pad. Green represents NeuN neuronal staining. Contralateral= ventral horn contralateral to 
the site of injection; ipsilateral= ipsilateral to the site of injection. Blue scale bar, 500 µm; yellow 
scale bar, 200 µm. 
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Figure 2 Truncated SNAP-25 in ipsilateral L4 spinal cord segment. A.) Dorsal horn after 
intramuscular BTX-A (5 U/kg) injection into the gastrocnemius; B.) Ventral horn after 
intramuscular BTX-A (5 U/kg) injection into the gastrocnemius; C.) Ventral horn after saline and 
BTX-A (10U/kg) injection into the sciatic nerve and D.) Ventral horn after colchicine (5mM) 
and BTX-A (10U/kg) injection into the sciatic nerve. White arrows point to cleaved SNAP-25 
fibers (red immunoreactivity). Green represents NeuN neuronal staining. Scale bar, 100 µm. 
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Figure 3 Truncated SNAP-25 colocalizes with cholinergic neurons, but not astrocytes.  
A. Confocal image of 2 µm optical section of ventral horn ipsilateral to BTX-A (30U/kg, sc.) 
treatment, showing colocalization of cleaved SNAP-25 (green immunofluorescence) and ChAT 
(red).  
B. Cleaved SNAP-25 (green) did not colocalize with GFAP (red), marker of astrocytes. Scale 
bars, 50 µm. 
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Graphical abstract 
 
Occurrence of cleaved SNAP-25 in ipsilateral lumbal ventral horn following botulinum 
toxin A (30 U/ kg) subcutaneous injection into the rat hind paw 
 
 
 
 
 
 
